Screener
Aurinia Pharmaceuticals AUPH Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $83.22M+18.9% | $77.71M+24.4% | $77.11M+28.8% | $73.47M+8.4% | $70.01M+22.4% | ||
| $6.56M-7.9% | $6.51M-24.1% | $8.8M+58.5% | $8.18M+35.5% | $7.12M-20.1% | ||
| $76.67M+21.9% | $71.2M+32.1% | $68.32M+25.8% | $65.29M+5.8% | $62.89M+30.3% | ||
| 92.1%+2.3pp | 91.6%+5.4pp | 88.6%-2.1pp | 88.9%-2.2pp | 89.8%+5.4pp | ||
| $13.05M+75.6% | $7.47M+30.1% | $10.9M+34.4% | $8.44M+177% | $7.43M+82.2% | ||
| $23.51M-9.6% | $22.03M+8.3% | $29.26M-21.0% | $26.18M-38.2% | $26.02M-42.1% | ||
| $36.88M-26.1% | $36.28M-10.7% | $43.88M-28.7% | $43.72M-22.0% | $49.93M-15.0% | ||
| $46.34M+131% | $41.42M+89.6% | $33.24M+2,092% | $29.75M+153% | $20.08M+1,427% | ||
| 55.7%+27.0pp | 53.3%+18.3pp | 43.1%+45.9pp | 40.5%+23.2pp | 28.7%+31.3pp | ||
| $948K-15.1% | $1.01M-5.2% | $1.05M-8.6% | $1.1M-9.0% | $1.12M-6.8% | ||
| $48.79M+120% | $43.93M+80.4% | $35.69M+2,943% | $31.96M+116% | $22.16M+1,399% | ||
| $11.37M+1,669% | $9.57M+852% | -$175.1M— | $411K-10.1% | $643K-14.9% | ||
| $37.41M+73.9% | $34.36M+47.2% | $210.79M+14,651% | $31.55M+120% | $21.51M+2,880% | ||
| 45%+14.2pp | 44.2%+6.8pp | 273.4%+271pp | 42.9%+21.8pp | 30.7%+29.5pp | ||
| $0.28+75.0% | $0.25+56.3% | $1.53+15,200% | $0.23+130% | $0.16+1,500% | ||
| $51.18M+105% | $46.24M+73.2% | $38.1M+1,093% | $34.61M+108% | $24.95M+649% | ||
| 61.5%+25.9pp | 59.5%+16.8pp | 49.4%+44.1pp | 47.1%+22.6pp | 35.6%+29.8pp | ||
| $46.34M+131% | $41.42M+89.6% | $33.24M+2,092% | $29.75M+153% | $20.08M+1,427% |
FAQ
- What is Aurinia Pharmaceuticals's revenue?
- Aurinia Pharmaceuticals (AUPH) generated $311.5M in revenue over the trailing twelve months, up 19.8% year over year.
- Is Aurinia Pharmaceuticals profitable?
- Aurinia Pharmaceuticals reported $314.1M in net income over the trailing twelve months, a 100.8% net margin.
- What are Aurinia Pharmaceuticals's profit margins?
- Gross margin is 90.4% and operating margin is 48.4%, with a 100.8% net margin.
- What is Aurinia Pharmaceuticals's earnings per share?
- Aurinia Pharmaceuticals's diluted EPS over the trailing twelve months is $2.29.
- Where does Aurinia Pharmaceuticals's income statement data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
